LENZ Therapeutics, Inc.
NASDAQ:LENZBiotechnology
-$0.42 today
- Market cap
- $100.86M
- Beta
- 1.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.48
Volume 0.62M
Average 0.89M
LENZ Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
LENZ Therapeutics, Inc.NASDAQ: LENZ
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 7.5% from a year ago
Cash & equivalents stood at $24.77M at the end of Q1 FY2026, up 7.5% from a year earlier and down 1.6% from the prior quarter. Over 3 fiscal years it compounded at -17.3% a year.
Context
- Cash & equivalents amounted to 9.1% of total assets at the end of Q1 FY2026, down 2.4 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +7.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 25.18M USD
- Year-over-year change
- +24.9%
- 4-year CAGR
- +8.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.18M | +24.9% |
| FY2024 | 2024-12-31 | 20.16M | -42.6% |
| FY2023 | 2023-12-31 | 35.14M | -20.9% |
| FY2022 | 2022-12-31 | 44.44M | +142.8% |
| FY2021 | 2021-12-31 | 18.31M | — |
Cash & Equivalents vs competitors
How LENZ compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +7.5% is the 2nd highest of 11, against a peer median of -19.3%.
- Cash & equivalents amounts to 9.1% of total assets for LENZ, versus a peer median of 15.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $242.65M USD | -0.9% | +14.1% | 88.2% | |
| Mar 2026 | $84.96M USD | -15.7% | -32.5% | 20.6% | |
| Mar 2026 | $70.78M USD | -15.5% | +11.8% | 13.3% | |
| Jun 2026 | $70.09M USD | -74.0% | -30.0% | 11.6% | |
| Mar 2026 | $64.11M USD | -30.2% | -30.5% | 21.8% | |
| Dec 2025 | €52.75M EUR | +6.1% | +8.4% | 77.8% | |
| Mar 2026 | $38.79M USD | +98.4% | -14.0% | 17.5% | |
| Mar 2026 | $24.77M USD | +7.5% | -17.3% | 9.1% | |
SPRYARS Pharmaceuticals, Inc. | Mar 2026 | $24.32M USD | -39.0% | -41.9% | 8.5% |
| Mar 2026 | $23.71M USD | -36.1% | -16.4% | 8.6% | |
| Mar 2026 | $11.24M USD | -23.0% | -14.5% | 9.0% | |
| Peer median (excluding LENZ) | — | -19.3% | -15.4% | 15.4% | |
Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 18.31M | 44.44M | 35.14M | 20.16M | 25.18M |
| Short-term Investments | 0 | 220.5M | 30.65M | 188.87M | 267.17M |
| Net Receivables | 0 | 0 | 0 | 0 | 2.43M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 16K | 2.2M | 1.45M | 114K | (2.43M) |
| Total Current Assets | 18.32M | 46.64M | 67.24M | 211.92M | 292.35M |
| Property, Plant & Equipment (Net) | 10K | 279K | 372K | 1.99M | 1.92M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2K | 31K | 2.76M | 1.4M | 2.54M |
| Total Non-current Assets | 12K | 310K | 3.13M | 3.39M | 4.46M |
| Total Assets | 18.34M | 46.95M | 70.38M | 215.3M | 305.88M |
| Account Payables | 460K | 4.76M | 5.71M | 4.26M | 4.17M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 347K | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 1.25M | 9.5M | 18.51M | 10.41M | 21.19M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 31.3M | 61.47M | 144.38M | 0 | 0 |
| Total Non-current Liabilities | 31.3M | 61.62M | 144.57M | 814K | 350K |
| Total Liabilities | 32.55M | 71.12M | 163.09M | 11.22M | 21.54M |
| Common Stock | 1K | 10K | 10K | 1K | 1K |
| Retained Earnings | (14.47M) | (25.28M) | (95.25M) | (145.01M) | (227.14M) |
| Accumulated OCI | 0 | (1.05M) | 6K | 196K | 242K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (14.21M) | (24.17M) | (92.71M) | 204.08M | 284.34M |
| Total Debt | 0 | 250K | 329K | 1.38M | 815K |
| Net Debt | (18.31M) | (44.19M) | (34.81M) | (18.78M) | (24.36M) |
LENZ Therapeutics, Inc.
NASDAQ:LENZ
Intrinsic Alpha fair value
Locked
Current Price
$3.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.